fluorouracil + docetaxel + S-1 + oxaliplatin

The combination of **fluorouracil, docetaxel, S-1, and oxaliplatin** is a multi-agent chemotherapy regimen primarily investigated for the treatment of advanced or metastatic gastric cancer. Each component has an antineoplastic mechanism: - **Fluorouracil** is a pyrimidine analog that inhibits thymidylate synthase, blocking DNA synthesis. - **Docetaxel** is a taxane-class agent that stabilizes microtubules against depolymerization, inhibiting cell division. - **S-1** combines tegafur (a prodrug of fluorouracil), gimeracil (which inhibits fluorouracil degradation), and potassium oteracil (which reduces fluorouracil GI toxicity), thus enhancing and modulating 5-FU activity[3]. - **Oxaliplatin** is a platinum-based compound that causes DNA crosslinking and apoptosis. This multi-drug regimen is used as neoadjuvant, perioperative, or first-line therapy for locally advanced, unresectable, or recurrent gastric cancer, with evidence for efficacy and tolerability.